Morales-Conde, MacarenaLópez-Ibáñez, NatividadCalvete-Candenas, JulioMendonça, Francisco Manuel Ildefonso2023-01-252023-01-252019-05-09http://hdl.handle.net/10668/13967Toxic epidermal necrolysis is a condition with massive keratinocyte apoptosis, and it is associated with high mortality rates. Fulvestrant, an estrogen receptor antagonist, is indicated in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. To our knowledge, this is the first described case of toxic epidermal necrolysis due to fulvestrant. A 56-year-old woman received 500 mg of intramuscular fulvestrant monthly for metastatic ductal carcinoma of the breast. Five days after the first dose, the patient presented with a maculopapular rash that evolved to blisters, and a detachment of the epidermis in over 30% of the total body surface area. Histological analysis was compatible with toxic epidermal necrolysis. Fulvestrant was discontinued, topical management and supportive care were initiated.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/Brain NeoplasmsEstrogen Receptor AntagonistsFemaleFulvestrantHumansMiddle AgedNecrosisSkinStevens-Johnson Syndromeresearch article31090829open access10.1590/abd1806-4841.201979641806-4841PMC6486080http://www.scielo.br/pdf/abd/v94n2/0365-0596-abd-94-02-0218.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486080/pdf